Etigilimab Drug Asset Due Diligence Report 2026

This Etigilimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Etigilimab can convert its Monoclonal antibody profile and TIGIT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Etigilimab (query alias: Etigilimab)
Modality / target	Monoclonal antibody; TIGIT; TIGIT inhibitors
Highest global status	Phase 2
Originator	Mereo BioPharma 5, Inc.
Active developers	Mereo BioPharma Group Plc, The University of Texas MD Anderson Cancer Center

The MCP disease footprint includes Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05026606	Phase 2	Active, not recruiting	20	Primary endpoint not disclosed in English source
NCT04761198	Phase 1/2	Completed	76	Primary endpoint not disclosed in English source
NCT03119428	Phase 1	Terminated	33	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Phase 2; n=23; evaluation: Not stated in English source. Reported fields: ORR = 15 % (95%CI, 3.2 - 37.9)

EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer.

Phase 2; n=23; evaluation: Positive. Reported fields: ORR = 15.0 % ( 3.2 - 37.9)

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Phase 1/2; n=63; evaluation: Positive. Reported fields: ORR = 43 % ; ORR = 17 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Etigilimab addresses Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2019-06-13	Celgene Walks Away from Licensing Deal with Beleaguered OncoMed	Phase 1	US$155.0M upfront; US$30.6M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer”. The milestone feed surfaced a patent-application signal described as “Cyclin-dependent kinase (CDK) 12 and/or CDK13 inhibitor combinations and uses thereof”. The milestone feed surfaced a patent-application signal described as “Combinations treatments of diacylglycerol kinase (DGK) alpha inhibitors and other therapies”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO